Celcuity, Inc. (CELC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$64.04-7.51%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CELC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
CELC — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…
Why it matters: More follow-up can show whether the trial's gains last and whether safety remains manageable. This helps test the results beyond the first data readout.
Watch forA fourth-quarter update shows continued treatment benefit and no rise in treatment stops from side effects.
Also watch forA fourth-quarter update shows less benefit with longer follow-up. Or, it shows more patients stop treatment.
Why it matters: The larger trial tests gedatolisib in patients whose cancer responds to hormone therapy and those whose cancer resists it. Clear progress could support wider use as a first treatment.
Supportive ifThe next company update confirms enrollment or a set goal for both VIKTORIA-2 studies.
Worry ifThe company reports a delay, pause, or smaller scope for either VIKTORIA-2 study.
Why it matters: Celcuity is still losing money while building its drug launch and running trials. Cash runway matters because management aims to fund operations through 2027.
Watch forThe November 11 report shows cash and investments near or above the Q2 level of $754 million. Funds cover operations through 2027.
Also watch forCash and investments fall well below $754 million. Management no longer says funds cover operations through 2027.
Why it matters: The filing could extend gedatolisib to patients with PIK3CA mutations. The trial found longer time without disease growth than alpelisib.
Supportive ifCelcuity confirms it submitted the VIKTORIA-1 PIK3CA mutant sNDA to the FDA.
Worry ifThe sNDA is not submitted, or the FDA declines to accept it for review.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$284 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $611 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,097 loss on $10,000 · 61.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The first shipments test whether Celcuity can turn FDA approval into a real launch. The NCCN lists the drug as a preferred Category 1 option.
Supportive ifCompany updates confirm shipments began by late Q3 2026. The company is filling commercial orders.
Worry ifBy the November 11, 2026 earnings update, shipments have not begun or the launch is delayed.